KLK9

From Wikipedia, the free encyclopedia
Kallikrein-related peptidase 9
Identifiers
SymbolsKLK9; KLK-L3; KLKL3
External IDsOMIM: 605504 MGI: 1921082 HomoloGene: 40832 ChEMBL: 3029 GeneCards: KLK9 Gene
EC number3.4.21.-
Orthologs
SpeciesHumanMouse
Entrez284366101533
EnsemblENSG00000213022ENSMUSG00000047884
UniProtQ9UKQ9Q32M27
RefSeq (mRNA)NM_012315NM_028660
RefSeq (protein)NP_036447NP_082936
Location (UCSC)Chr 19:
51.5 – 51.51 Mb
Chr 7:
43.79 – 43.8 Mb
PubMed search

Kallikrein-related peptidase 9 also known as KLK9 is an enzyme which in humans is encoded by the KLK9 gene.[1]

Function

KLK9 belongs to the kallikrein subgroup of serine proteases, which have diverse physiologic functions in many tissues.[2][3][4] KLK9 is primarily expressed in thymus, testis, spinal cord, cerebellum, trachea, mammary gland, prostate, brain, salivary gland, ovary, and skin.[1]

Clinical significance

KLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines and is a potential prognostic marker for early-stage ovarian[5] and breast cancer patients.[6]

References

  1. 1.0 1.1 Yousef GM, Diamandis EP (April 2000). "The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9)". Genomics 65 (2): 184–94. doi:10.1006/geno.2000.6159. PMID 10783266. 
  2. "Entrez Gene: KLK9". 
  3. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM (June 2006). "A comprehensive nomenclature for serine proteases with homology to tissue kallikreins". Biol. Chem. 387 (6): 637–41. doi:10.1515/BC.2006.082. PMID 16800724. 
  4. Diamandis, Eleftherios P.; Deperthes, David; Lundwall, Åke (June 2006). "Proceedings of the 1st International Symposium on Kallikreins, Lausanne, Switzerland, September 1-3 , 2005". Biol. Chem. 387 (6): 635–824. doi:10.1515/BC.2006.081. PMID 16800723. 
  5. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D (November 2001). "Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker". Cancer Res. 61 (21): 7811–8. PMID 11691797. 
  6. Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzone R, Biglia N, Maggiorotto F, Roagna R, Sismondi P, Diamandis EP (March 2003). "The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer". Breast Cancer Res. Treat. 78 (2): 149–58. doi:10.1023/A:1022931403825. PMID 12725415. 

Further reading

  • Yousef GM, Kyriakopoulou LG, Scorilas A, et al. (2001). "Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.". Cancer Res. 61 (21): 7811–8. PMID 11691797. 
  • Yousef GM, Luo LY, Diamandis EP (1999). "Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4.". Anticancer Res. 19 (4B): 2843–52. PMID 10652563. 
  • Grimwood J, Gordon LA, Olsen A, et al. (2004). "The DNA sequence and biology of human chromosome 19.". Nature 428 (6982): 529–35. doi:10.1038/nature02399. PMID 15057824. 
  • Gan L, Lee I, Smith R, et al. (2000). "Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region.". Gene 257 (1): 119–30. doi:10.1016/S0378-1119(00)00382-6. PMID 11054574. 

External links

  • The MEROPS online database for peptidases and their inhibitors: S01.307
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.